On January 22, AbbVie announced that risankizumab injection had been approved in China for a new indication: treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, lost response to, or been intolerant of conventional therapy or biologic therapy.
In June 2024, risankizumab was approved in the United States for ulcerative colitis, becoming the first IL-23-specific inhibitor approved for both moderately to severely active ulcerative colitis and moderately to severely active Crohn’s disease.
This approval was supported by two Phase III trials evaluating risankizumab in moderately to severely active ulcerative colitis: the 12-week induction study INSPIRE and the 52-week maintenance study COMMAND.
In March 2023, AbbVie announced positive pivotal results from INSPIRE. The study showed that adults with moderately to severely active ulcerative colitis treated with risankizumab achieved clinical remission at week 12 based on the modified Mayo score, as well as all secondary study endpoints. Clinical remission was achieved in 20.3% of risankizumab-treated patients versus 6.2% in the placebo group. At week 12, the proportion of patients achieving endoscopic improvement was significantly higher with risankizumab than with placebo, 36.5% versus 12.1%. Histologic-endoscopic mucosal improvement at week 12 was achieved in 24.5% of risankizumab-treated patients versus 7.7% in the placebo group.
In June 2023, AbbVie announced that risankizumab met the primary endpoint and key secondary endpoints in the 52-week Phase III maintenance study COMMAND in ulcerative colitis. At week 52, the proportions of patients achieving clinical remission were significantly higher in the 180 mg and 360 mg risankizumab groups, at 40% and 38%, respectively, versus 25% in the induction-only control group.
At week 52, 51% of patients receiving 180 mg risankizumab and 48% receiving 360 mg achieved endoscopic improvement, versus 32% in the induction-only control group. Histologic-endoscopic mucosal improvement at week 52 was achieved by 43% and 42% in the 180 mg and 360 mg groups, respectively, versus 23% in the control group. Steroid-free clinical remission at week 52 was also significantly higher with 180 mg or 360 mg risankizumab, at 40% and 37%, respectively, versus 25% in the control group.
Risankizumab, marketed as Skyrizi, is an IL-23 inhibitor that selectively blocks a series of IL-23-mediated immune inflammatory responses by binding to the IL-23 p19 subunit.
The drug was originally developed by Boehringer Ingelheim. AbbVie obtained development and global commercialization rights in 2016. It was first approved in Japan in March 2019 and subsequently approved by the FDA and the European Medicines Agency.
In China, the NMPA first approved risankizumab in March 2025 for adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to, lost response to, or were intolerant of conventional or biologic therapy. Approved formulations included risankizumab injection and risankizumab injection for subcutaneous administration. This latest decision is its second approved indication in China.
To date, the drug has been approved globally for multiple indications including Crohn’s disease, plaque psoriasis, generalized pustular psoriasis, erythrodermic psoriasis, and psoriatic arthritis. In plaque psoriasis, risankizumab has already outperformed ustekinumab, adalimumab, secukinumab, and apremilast.
After launch, risankizumab sales rose rapidly, reaching US$2.939 billion, US$5.165 billion, and US$7.763 billion in 2021, 2022, and 2023, respectively. Global sales reached US$11.718 billion in 2024, putting it into the US$10 billion club.